At T2DXX, our goal is to share the voice of the T2 person, the authentic lived experience. One of the ways T2DXX does this is through submissions to the Canadian Agency For Drugs And Technologies In Health.
CADTH is a not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies. This includes drugs, medical devices (including dental and surgical), procedures, and diagnostic tests. They help shape the landscape of our healthcare system to benefit patients.
Your input has and will continue to influence health care decision-makers to make informed decisions about new products that enter the market. Over the past two years, we’ve made two large submissions to this agency with your help. We’ll continue to make submissions focusing on your experiences. Currently, there are only two patient groups in Canada that make submissions to this agency, Diabetes Canada, and us, the Type 2 Diabetes Experience Exchange. Our submission stands out in that we collected actual experiences using the drugs and focusing on the financial and psychosocial impact of managing a chronic illness.
OUR FIRST COMMON DRUG REVIEW
Insulin degludec + liraglutide (trademark name Xultophy® )
Xultophy® combines two medications together in one injection – insulin degludec and liraglutide.
Insulin degludec is a long-acting insulin that works for up to 42 hours. The proprietary name, or how you might know it, is Tresiba®. Liraglutide, is part of a group of medications called glucagon-like peptide-1 (GLP-1) receptor agonists. You know it as Victoza®.
The long-acting insulin works to manage blood glucose levels throughout the 42 hour period while the liraglutide helps your pancreas to produce more insulin when your blood glucose is higher. It also slows gastric (stomach) emptying and helps to repress hepatic (liver) gluconeogenesis (which is the process of the liver breaking down stored glycogen into glucose).
CADTH SUBMISSION FINDINGS
One of the things we find important is sharing the lived type 2 diabetes experience. To shed light on living with a chronic disease and how it impacts the day to day lives of those affected. This affects decisions of use of certain drugs and medications, and how people actually use them in the real world.
From our submission, one area that stood out from your stories was the psychosocial impact of living with type 2.
CADTH reviewers and expert committee members found your input useful, particularly with regards to:
Shedding light on the stigma associated with diabetes and the psychosocial impact it has on patients. The input you shared helped paint a picture of the ways in which misconceptions and stigma from families, the public, and health care professionals, unfairly contribute to feelings of shame and guilt in patients.
Discussing how diabetes management is especially difficult for lower-income individuals. Committee members heard how costly medications and healthy lifestyle expenses can lead to inconsistent prescription use, and subsequent health complications and work absenteeism.
We’ve also made a significant impact on developing policy and protocol:
Our “group’s input helped CADTH reviewers develop the review protocol by identifying important outcomes, including diabetes-related morbidity, quality of life, and body weight.”
And the final exciting finding we’ve made is an impact overall on the CADTH drug review process for future submissions:
In the future, it would be valuable to learn how many patients were involved and the countries and/or provinces in which they reside, to provide context to the perspectives that were offered.
FOR MORE INFORMATION
OUR NEXT REVIEW
Check back for our second review on an oral semiglutide drug.